CA3136126A1 - Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum - Google Patents

Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum

Info

Publication number
CA3136126A1
CA3136126A1 CA3136126A CA3136126A CA3136126A1 CA 3136126 A1 CA3136126 A1 CA 3136126A1 CA 3136126 A CA3136126 A CA 3136126A CA 3136126 A CA3136126 A CA 3136126A CA 3136126 A1 CA3136126 A1 CA 3136126A1
Authority
CA
Canada
Prior art keywords
lysin
gram
lysin polypeptide
lytic activity
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136126A
Other languages
English (en)
French (fr)
Inventor
Raymond Schuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contrafect Corp
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of CA3136126A1 publication Critical patent/CA3136126A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3136126A 2019-04-05 2020-04-03 Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum Pending CA3136126A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830207P 2019-04-05 2019-04-05
US62/830,207 2019-04-05
PCT/US2020/026681 WO2020206327A1 (en) 2019-04-05 2020-04-03 Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum

Publications (1)

Publication Number Publication Date
CA3136126A1 true CA3136126A1 (en) 2020-10-08

Family

ID=72667504

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136126A Pending CA3136126A1 (en) 2019-04-05 2020-04-03 Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum

Country Status (11)

Country Link
US (1) US20220160843A1 (https=)
EP (1) EP3946609A4 (https=)
JP (1) JP2022526978A (https=)
KR (1) KR20210148320A (https=)
CN (1) CN114040773A (https=)
AU (1) AU2020256258A1 (https=)
BR (1) BR112021019430A2 (https=)
CA (1) CA3136126A1 (https=)
IL (1) IL286941A (https=)
MX (1) MX2021012166A (https=)
WO (1) WO2020206327A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24750B1 (es) * 2020-11-19 2025-06-11 Centro De Investig Y Desarrollo De Medicamentos Cidem Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
CN116200418A (zh) * 2021-12-01 2023-06-02 华南农业大学 一种筛选铜绿假单胞菌LasR基因调控网络未知基因突变体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5701777B2 (ja) * 2009-02-06 2015-04-15 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
AU2015279705B2 (en) * 2014-06-26 2021-04-01 The Rockefeller University Acinetobacter lysins
AU2016324307B2 (en) * 2015-09-17 2021-10-21 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
BR112020011433A2 (pt) * 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
CN108103050A (zh) * 2018-02-11 2018-06-01 中国医药集团总公司四川抗菌素工业研究所 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
WO2020046747A1 (en) * 2018-08-23 2020-03-05 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Also Published As

Publication number Publication date
MX2021012166A (es) 2021-11-03
EP3946609A1 (en) 2022-02-09
EP3946609A4 (en) 2023-05-03
US20220160843A1 (en) 2022-05-26
BR112021019430A2 (pt) 2021-11-30
KR20210148320A (ko) 2021-12-07
AU2020256258A1 (en) 2021-11-04
JP2022526978A (ja) 2022-05-27
WO2020206327A1 (en) 2020-10-08
IL286941A (en) 2021-10-31
CN114040773A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
US12121568B2 (en) Identification of lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa
CN108348574B (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
CA3095484A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20210260070A1 (en) Lysin cf-301 resensitizes methicillin-resistant staphylococcus aureua (mrsa) to penicillin derivatives and first generation cephalosporins
CN112118861A (zh) 修饰的PlySs2溶素及其用途
Kumar Natural peptides and their synthetic congeners acting against Acinetobacter baumannii through the membrane and cell wall: latest progress
CA3136126A1 (en) Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum
CA3096236A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
EP4058468A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
US20220160842A1 (en) Method of treating infective endocarditis
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
WO2020093057A1 (en) Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
WO2022261360A1 (en) Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾ＰｌｙＳｓ２溶解素及び抗生物質の組合せ